Palforzia Is Ending, But Food Allergy Treatment Is Moving FAST

When headlines announced the discontinuation of Palforzia, the first FDA-approved peanut allergy treatment, many families understandably wondered: Does this mean food allergy treatment isn't working? In this episode of The Immune Edit, Dr. Doug Jones explains why the answer is a resounding no. Dr. Jones shares his perspective on why Palforzia struggled commercially, the challenges of fitting highly individualized care into a rigid pharmaceutical model, and what the future of food allergy treatment actually looks like. He also pulls back the curtain on the work of FAST (Food Allergy Support Team), a global network of clinicians collaborating to advance patient-centered food allergy care through real-world experience, innovation, and outcomes. This conversation explores: • Why Palforzia's discontinuation is not a setback for food allergy treatment • The history and evolution of oral immunotherapy (OIT) • Why personalized treatment matters more than one-size-fits-all solutions • Emerging approaches including OIT, sublingual immunotherapy, biologics, and combination therapies • The importance of accessibility, affordability, and reducing treatment burden • How collaboration—not competition—will shape the future of food allergy care Most importantly, this episode is about something bigger than peanut flour or pharmaceutical products. It's about helping families move from fear to freedom, finding treatments that fit the individual, and building a future where food allergy care is driven by patient outcomes rather than product-centered agendas. The future of food allergy treatment isn't disappearing. In many ways, it's just getting started.